Prof. Kui Liu | Breast Cancer | Best Researcher Award

Zibo Central Hospital | China

AUTHOR PROFILE

Scopus

KUI LIU, Ph.D. – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Kui Liu embarked on a robust academic journey in clinical and diagnostic sciences:

2002-2005: Completed a degree in Clinical Laboratory Medicine from Linyi Medical College, China.
2012-2015: Pursued a master’s degree in Clinical Laboratory Diagnostics at Jiangsu University, Zhenjiang, China.
2016-2020: Earned a Ph.D. in Immunology from Southeast University, Nanjing, China, contributing significantly to the field with innovative research in immune responses and diagnostics.

💼 PROFESSIONAL ENDEAVORS

Kui Liu has accumulated extensive clinical and technical experience over nearly two decades:

2020-Present: Associate Chief Technician at the Center of Translational Medicine, Zibo Central Hospital, where he plays a key role in integrating research with clinical applications.
2015-2016: Worked as a Docimaster at the Blood Bank of the First Hospital of Zibo, focusing on blood storage and safety protocols.
2008-2012: Served as a Docimaster at the same institution, ensuring high-quality diagnostic practices.
2005-2008: Began his career as a Docimaster in the Laboratory Department, excelling in clinical diagnostics.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER

Kui Liu’s research is centered on advancing the fields of immunology and clinical diagnostics, with a focus on:

The study of immune responses in various pathological conditions.
Development of innovative diagnostic tools and techniques.
Translation of scientific research into clinical solutions.

His work on immune mechanisms and diagnostic technologies has led to groundbreaking advancements in translational medicine.

💡 FUNDING AND RESEARCH IMPACT

Kui Liu has been a driving force behind several high-impact research projects, securing prestigious grants to fund cutting-edge studies:

Grant no. 81602330: Principal Investigator for the National Natural Science Foundation of China (2017-2019), focusing on immunological research.
Grant no. 81972002: Co-Investigator for the National Natural Science Foundation of China (2019-2022), contributing to collaborative advancements in the field.
Grant no. J18KA299: Co-Investigator in the Shandong Province Higher Educational Science and Technology Program (2019-2021).
Grant no. ZR2015PH056: Co-Investigator for the Natural Science Foundation of Shandong Province (2015-2016).
Grant no. CXLX13_689: Principal Investigator for the Innovation Project of Cultivating Graduates of Jiangsu Province (2013-2015).

🌍 IMPACT AND INFLUENCE

Innovator in Translational Medicine: Kui Liu has bridged the gap between laboratory research and clinical application, enhancing diagnostic capabilities in immunology.
National and Regional Contributions: Through leadership in provincial and national projects, he has elevated the standards of diagnostic medicine across China.
Collaboration and Mentorship: Actively fosters collaborations and guides aspiring researchers, contributing to the growth of the next generation of medical scientists.

📚 ACADEMIC CITES AND RECOGNITION

Kui Liu has received widespread recognition for his contributions, reflected in numerous citations and acknowledgments in scientific journals. His findings have influenced medical practices and inspired continued exploration in immunology.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Kui Liu’s career is a testament to his commitment to advancing medical science. His future endeavors include:

Leading innovative studies in immunological diagnostics.
Expanding the applications of translational medicine.
Continuing to inspire young researchers through mentorship and collaboration.

🌟CONCLUSION

Dr. Kui Liu’s remarkable journey from foundational clinical studies to advanced immunological research exemplifies a career dedicated to innovation, excellence, and impact. His contributions to translational medicine and diagnostics have not only advanced scientific understanding but also improved clinical practices, particularly in immunology.

📊🔬NOTABLE PUBLICATION:

1. Title: LncRNA DANCR-miR-758-3p-PAX6 Molecular Network Regulates Apoptosis and Autophagy of Breast Cancer Cells
  - Authors: Zhang, X.H., Li, B.F., Ding, J., Ma, F.X., Wu, X.Y.
  - Journal: Cancer Management and Research
  - Year: 2020
1. Title: LncRNA PVT1 Regulates Gallbladder Cancer Progression through miR-30d-5p
  - Authors: Liu, K., Xu, Q.
  - Journal: Journal of Biological Regulators and Homeostatic Agents
  - Year: 2020
1. Title: TIPE1 Inhibits Osteosarcoma Tumorigenesis and Progression by Regulating PRMT1 Mediated STAT3 Arginine Methylation
  - Authors: Yang, M., Zhang, Y., Liu, G., Liu, Q., Zhao, P.
  - Journal: Cell Death and Disease
  - Year: 2022
1. Title: CircRNA hsa_circ_0008500 Acts as a miR-1301-3p Sponge to Promote Osteoblast Mineralization by Upregulating PADI4
  - Authors: Zhai, Q., Zhao, Y., Wang, L., Li, T., Wang, L.
  - Journal: Frontiers in Cell and Developmental Biology
  - Year: 2020
1. Title: miR-369-3p Inhibits Tumorigenesis of Hepatocellular Carcinoma by Binding to PAX6
  - Authors: Xu, Q., Liu, K.
  - Journal: Journal of Biological Regulators and Homeostatic Agents
  - Year: 2020

Introduction: Personalized cancer treatment represents a paradigm shift in oncology, moving away from one-size-fits-all approaches and towards tailoring treatments based on an individual’s unique genetic, molecular, and clinical characteristics. This approach holds the promise of maximizing treatment efficacy while minimizing side effects, offering new hope for cancer patients.

Subtopics in Personalized Cancer Treatment:

Genomic Profiling: Genomic analysis of a patient’s tumor can identify specific genetic mutations and alterations that drive cancer growth. Targeted therapies are then designed to attack these specific molecular vulnerabilities, leading to more effective treatment.

Immunotherapy and Immune Profiling: Personalized cancer treatment extends to immunotherapy, where the patient’s immune system is harnessed to fight cancer. Immune profiling helps identify immune checkpoints and tumor-specific antigens, aiding in the selection of suitable immunotherapies.

Biomarker-Based Therapy: Biomarkers such as hormone receptors, HER2 status, and PD-L1 expression guide treatment decisions in breast, lung, and other cancers. Personalization ensures that patients receive therapies tailored to their tumor’s unique characteristics.

Treatment Resistance Mitigation: Personalized approaches are essential in combating treatment resistance. Continuous monitoring and adaptation of treatment regimens based on evolving tumor profiles can help overcome resistance and extend the duration of response.

Clinical Trial Matching: Personalized treatment extends to the realm of clinical trials, where patients are matched with experimental therapies that align with their tumor’s genetic makeup. This accelerates drug development and provides patients with access to cutting-edge treatments.

These subtopics highlight the transformative potential of personalized cancer treatment, emphasizing its role in optimizing patient outcomes, minimizing adverse effects, and advancing the field of oncology towards precision medicine.